Tin tức & Cập nhật

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023 bởiJairia Dela Cruz

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023
How to prevent CVD and early death? Take a walk
How to prevent CVD and early death? Take a walk
12 Oct 2023